Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong

被引：0
|
作者：
Loong, H. H. [1 ]
Wong, C. K. H. [2 ]
Leung, L. K. S. [3 ]
Chan, C. P. K. [4 ]
Chang, A. [5 ]
Gibbs, M. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Novartis Oncol Hong Kong, Med Affairs, Hong Kong, Peoples R China
[5] Novartis Oncol Hong Kong, Market Access, Hong Kong, Peoples R China
[6] Novartis Oncol, Dubai, U Arab Emirates
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY UNTREATED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
    Xie, J.
    Knoll, S.
    Slowley, A.
    Bensimon, A.
    Vieira, J.
    Chilcott, J.
    Paisley, S.
    Zhou, Z.
    [J]. VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [2] Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
    Loong, Herbert H.
    Wong, Carlos K. H.
    Leung, Linda K. S.
    Chan, Catherine P. K.
    Chang, Andrea
    Zhou, Zheng-Yi
    Xie, Jipan
    Gibbs, Meaghan
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [3] Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
    Herbert H. Loong
    Carlos K. H. Wong
    Linda K. S. Leung
    Catherine P. K. Chan
    Andrea Chang
    Zheng-Yi Zhou
    Jipan Xie
    Meaghan Gibbs
    [J]. Cost Effectiveness and Resource Allocation, 18
  • [4] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    [J]. Advances in Therapy, 2019, 36 : 1114 - 1125
  • [5] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    [J]. ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [6] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [7] Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    [J]. ADVANCES IN THERAPY, 2020, 37 (02) : 971 - 972
  • [8] Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    [J]. Advances in Therapy, 2020, 37 : 971 - 972
  • [9] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Tsuji, Takahiro
    Nomizo, Takashi
    Yasuda, Yuto
    Yamamoto, Tomoko
    Ajimizu, Hitomi
    Hirai, Toyohiro
    [J]. IN VIVO, 2018, 32 (06): : 1587 - 1590
  • [10] Finding a place for ceritinib in the landscape of ALK-positive non-small cell lung cancer
    Shum, Elaine
    Gandhi, Leena
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S215 - S218
12345